Abstract
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer, occurring in <1% of all lung tumors. PSC is highly resistant to conventional cytotoxic chemotherapies and confers a poor prognosis. Two single-arm, multicenter phase-II trials were conducted to evaluate the efficacy and safety of PD-1 inhibitors in patients with PSC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
